NRG BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer.
Publication
, Conference
Chmura, SJ; Winter, KA; Salama, JK; Woodward, WA; Borges, VF; Al-Hallaq, HA; Matuszak, M; Jaskowiak, NT; Milano, MT; Bandos, H; White, JR
Published in: JOURNAL OF CLINICAL ONCOLOGY
May 20, 2015
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2015
Volume
33
Issue
15
Location
Chicago, IL
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Chmura, S. J., Winter, K. A., Salama, J. K., Woodward, W. A., Borges, V. F., Al-Hallaq, H. A., … White, J. R. (2015). NRG BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 33). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. https://doi.org/10.1200/jco.2015.33.15_suppl.tps1105
Chmura, Steven J., Kathryn A. Winter, Joseph Kamel Salama, Wendy A. Woodward, Virginia F. Borges, Hania A. Al-Hallaq, Martha Matuszak, et al. “NRG BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.tps1105.
Chmura SJ, Winter KA, Salama JK, Woodward WA, Borges VF, Al-Hallaq HA, et al. NRG BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer. In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2015.
Chmura, Steven J., et al. “NRG BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer.” JOURNAL OF CLINICAL ONCOLOGY, vol. 33, no. 15, AMER SOC CLINICAL ONCOLOGY, 2015. Wos, doi:10.1200/jco.2015.33.15_suppl.tps1105.
Chmura SJ, Winter KA, Salama JK, Woodward WA, Borges VF, Al-Hallaq HA, Matuszak M, Jaskowiak NT, Milano MT, Bandos H, White JR. NRG BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2015.
Published In
JOURNAL OF CLINICAL ONCOLOGY
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2015
Volume
33
Issue
15
Location
Chicago, IL
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences